Human Immunodeficiency Virus Infections
Conditions
Keywords
Treatment-naive, rilpivirine, India
Brief summary
The primary purpose of the study is to evaluate the efficacy of rilpivirine (RPV)-based regimen in human immunodeficiency virus type 1 (HIV-1) infected, antiretroviral (ARV) treatment-naive participants, as determined by the percentage of virologic responders defined as having HIV-1 ribonucleic acid (RNA) less than 400 copies/ milliliter (mL) at Week 24.
Interventions
Participants will receive rilpivirine 25 mg tablet orally once daily.
DRUGTenofovir Disoproxil Fumarate (TDF)/Lamivudine (3TC)
Participants will receive 1 fixed dose combination tablet once daily containing 300 mg TDF and 300 mg 3TC.
Sponsors
Janssen Research & Development, LLC
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Must have documented human immunodeficiency virus type 1 (HIV-1) infection * Must be antiretroviral (ARV) treatment-naïve * Have plasma HIV-1 ribonucleic acid (RNA) less than (\<) 100,000 copies/milliliter (mL) at screening visit * Have cluster of CD4+ T-cell count (greater than) \>200/ cubic millimeter (mm\^3) at screening visit * Women of childbearing potential must have a negative serum (beta human chorionic gonadotropin \[beta hCG\]) pregnancy test at screening; and a negative urine (or serum, if required by local regulations) pregnancy test before the first dose of study
Exclusion criteria
* History of any primary nucleo(t)side reverse transcriptase inhibitor (N\[t\]RTI) or non-nucleoside reverse transcriptase inhibitor (NNRTI) mutations (if testing performed locally, and results are available), as defined by the current International AIDS (acquired immunodeficiency syndrome) Society-United States (USA) (International Antiviral Society-USA) 2017 guidelines * Has clinical or laboratory evidence of significantly decreased hepatic function or decompensation, irrespective of liver enzyme levels (hepatic insufficiency) * Diagnosed with acute viral hepatitis at screening or before baseline * Infected with Mycobacterium tuberculosis which is likely to require rifampicin-based treatment during the study * Has a Grade 3 or 4 laboratory abnormality as defined by the Division of AIDS (DAIDS) for Grading the Severity of Adult and Pediatric Adverse Events criteria with the following exceptions unless clinical assessment foresees an immediate health risk to the participant: (a) Preexisting diabetes or with asymptomatic glucose Grade 3 or 4 elevations (b) Asymptomatic triglyceride or cholesterol elevations of Grade 3 or 4
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants who are Virologic Responders (HIV-1 RNA <400 Copies/mL) at Week 24 | Week 24 | Virologic responders are defined as participants having viral load (plasma Human Immunodeficiency Virus-Type 1 Ribonucleic Acid \[HIV-1 RNA\] levels) less than (\<) 400 copies/milliliter (mL) at Week 24 (Food and Drug Administration \[FDA\]-defined snapshot analysis). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants who are Virologic Responders (HIV-1 RNA <50 Copies/mL) at Week 24 | Week 24 | Virologic responders are defined as participants having viral load (plasma HIV-1 RNA levels) \<50 copies/mL at Week 24 (FDA-defined snapshot analysis). |
| Percentage of Participants who are Virologic Responders (Plasma HIV-1 RNA Levels <50, <400 and <1,000 Copies/mL) at Week 48 | Week 48 | Virologic responders are defined as participants having viral load (plasma HIV-1 RNA levels) \<50, \<400 and \<1,000 copies/mL at Week 48 (FDA-defined snapshot analysis). |
| Absolute Value in Cluster of Differentiation 4 Positive (CD4+) T-Cell Count at Weeks 24 and 48 | At Weeks 24 and 48 | CD4+T cell absolute counts will be determined at Weeks 24 and 48. |
| Change from Baseline in CD4+ T Cell Count at Weeks 24 and 48 | Baseline, Weeks 24 and 48 | Change from baseline in CD4+ T cell count will be determined at Weeks 24 and 48. |
| Percentage of Participants with Grade 3 and 4 Adverse Events (AEs), Serious Adverse Events (SAEs), and Participants Experiencing Premature Discontinuation due to AEs Through Week 48 | Through Week 48 | Percentage of participants with Grade 3 and 4 AEs will be assessed. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Percentage of participants who prematurely discontinued study due to AEs will also be analyzed. |
| Percentage of Participants with Laboratory Abnormalities | Up to Week 48 | Percentage of participants with laboratory abnormalities will be reported. |
| Number of Participant with Clinically Significant Change from Baseline in Laboratory Parameters | Baseline up to Week 48 | Number of participants with clinically significant change from baseline in laboratory parameters related to hematology, serum chemistry will be assessed. |
| Emergence of Viral Resistance Through Weeks 24 and 48 | Through Weeks 24 and 48 | Resistance analysis will be determined using genotypic analysis at the time of virological failure (that is, 2 consecutive plasma HIV-1 RNA levels greater than or equal to \[\>=\] 400 copies/mL through Weeks 24 and 48 of study treatment). |
| Percentage of Participant with Treatment Adherence (95%) Based on Tablet Count up to Weeks 24 and 48 | Up to Weeks 24 and 48 | Percentage of adherent participants as measure of treatment compliance will be assessed by tablet count. |
Countries
India
Outcome results
None listed